December 30, 2005
Genta Will Hold Conference Call To Update Investors On Regulatory Applications And Upcoming Milestones
December 29, 2005
Genta Files New Drug Application For FDA Approval of Genasense® Plus Chemotherapy For Patients With Advanced Or Refractory Chronic Lymphomatic Leukemia
December 12, 2005
Pilot Clinical Study Of Genasense® Plus Rituxan® and Fludarabine Shows Activity In Chronic Lymphocytic Leukemia
December 6, 2005
Annual Meeting of the American Society of Hematology Highlights Clinical Data with Genasense® and the Importance of its Target in Cancer
November 15, 2005
Genasense® Enhances Preclinical Activity of Tarceva using an Intermittent Dosing Schedule
November 7, 2005
Genta Announces 3rd Quarter 2005 Financial Results
November 1, 2005
Genasense Highlighted in Presentations at Chemotherapy Foundation Symposium
October 31, 2005
Genta Incorporated Hosts Conference Call to Discuss Third Quarter Highlights and Financial Results
October 28, 2005
Genta Incorporated to Present at Rodman & Renshaw Techvest 7<sup>th</sup> Annual Healthcare Conference
October 19, 2005
New Experimental Results Show Genasense® Enhances Radiation Therapy In Colon Cancer
September 19, 2005
Data from Phase 3 Trial of Genasense® Confirm Extended Durability of Remission and Benefit in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
September 16, 2005
Genta Appoints Richard J. Moran Senior Vice-President and Chief Financial Officer
September 16, 2005
Genta Senior Management to Highlight Clinical Progress of Genasense® and Antisense Technology at Meeting on Oligonucleotide Therapeutics
September 16, 2005
Industry Leaders in Pharmaceutical Sales, Marketing, and Alliance Management Appointed to Genta Incorporated Board of Directors
September 16, 2005
Genta Incorporated Adopts Stockholder Rights Plan
August 9, 2005
Genta Announces 2nd Quarter 2005 Financial Results and Corporate Highlights
August 8, 2005
Genta Announces Common Stock Offering Totaling Approximately $17.5 Million
August 3, 2005
Genta to Host Conference Call to Discuss Second Quarter Highlights and Financial Results
June 30, 2005
Genta Initiates European Regulatory Submission for Genasense®Plus Chemotherapy for Patients with Advanced Melanoma
June 30, 2005
Genta Initiates New Drug Application for Genasense®in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
June 20, 2005
Genta Incorporated Announces Webcast of 2005 Annual Shareholders Meeting
June 13, 2005
Genasense® plus Rituximab Reported Active in Patients with Relapsed Non-Hodgkin's Lymphoma
May 19, 2005
Genta Incorporated to Present at Needham & Co. Biotechnology Conference
May 17, 2005
Genta Announces Conference Call to Review First Quarter Highlights and Data Presented at the American Society of Clinical Oncology Annual Meeting
May 17, 2005
Multiple Presentations Report Active Combinations of Genasense® Plus Chemotherapy in Patients with Advanced Gastrointestinal Cancer
May 17, 2005
Genasense® Combinations with Chemotherapy Reported for Children with Solid Tumors and Adults with Extensive-Stage Small Cell Lung Cancer Final Data
May 16, 2005
Genasense® Phase 3 Results in Malignant Melanoma Updated at ASCO
May 13, 2005
Updated Analysis from Phase 3 Trial of Genasense® in CLL Shows Significant Increase in Duration of Major Responses
May 10, 2005
Genta and Aventis Terminate Genasense® Agreements
May 9, 2005
Genta Incorporated Announces First Quarter 2005 Financial Results<br /><em>Conference Call on May 18, 2005 to Review Financials, Milestones, and ASCO Presentations </em>
May 6, 2005
Genta to Release First Quarter 2005 Financial Results on May 9, 2005
May 5, 2005
Genasense® Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
April 28, 2005
Reports Show Correlations of Genasense® Levels with Target and Biomarker Effects in Patients with Acute Myelocytic Leukemia and Prostate Cancer
April 19, 2005
Genasense® Increases Antitumor Activity of Iressa® in Preclinical Models of Non-Small Cell Lung Cancer
March 23, 2005
Genta Incorporated to Present at Lehman Brothers Healthcare Conference
March 15, 2005
Genta Obtains Orphan Drug Designation for C-Myb Antisense (LR3001) in Chronic Myelocytic Leukemia
February 17, 2005
Genta Incorporated Announces Fourth Quarter and Year End 2004 Results
February 16, 2005
Genta Incorporated to Present at BIO CEO and Investor Conference
February 14, 2005
Genta Incorporated to Release 2004 Full Year and Fourth Quarter Results on Thursday, February 17, 2005; Conference call/webcast to follow
January 20, 2005
Genta Incorporated to Present at Piper Jaffray Healthcare Conference
